A Case of Adenomyosis Showing Size Reduction in a Follicular Lymphoma Patient Receiving Chemotherapy With R-Bendamustine
case-report
OA: closed
CC0
AI-generated summary
Adenomyosis in a follicular lymphoma patient significantly reduced in size and metabolic activity after receiving R-bendamustine chemotherapy, coinciding with chemotherapy-induced menopause.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
We describe a case of adenomyosis that reduced in size in a patient with lymphoma on receiving chemotherapy. A 48-year-old woman with worsening left flank pain was diagnosed with follicular lymphoma. [ 18 F]FDG PET/CT revealed multiple hypermetabolic lymph nodes in the bilateral cervical, axillary, mediastinal, mesenteric, retroperitoneal, iliac, and inguinal regions. In addition, adenomyosis with mild hypermetabolism was demonstrated on [ 18 F]FDG PET/CT. The size and metabolism of adenomyosis decreased after chemotherapy with R-bendamustine; in addition, along with decrease in estradiol levels, the patient experienced amenorrhea and hot flushes. The patient was diagnosed with chemotherapy-induced early menopause.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
References (9)
- Adenomyosis: A Sonographic Diagnosis via openalex
- How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic via openalex
- Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists via openalex
- W2131891646 via openalex
- W3094320124 via openalex
- W2067799640 via openalex
- W6754824627 via openalex
- W2104679539 via openalex
- W2107910796 via openalex
Source provenance
- europepmc
- last seen: 2026-06-18T06:15:08.409253+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-06-18T06:14:01.010302+00:00
License: CC0
· commercial use OK